Project Grant R01DK145468
Award Date 9/1/26
Completion Date 4/30/30
Dollars Obligated $598K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15213, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $814,500 to the University of Pittsburgh on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to fund research dissecting functional decompensation of end-stage liver disease and investigating the mechanism and impact of transcription factors on long-term functional reprogramming. The research examines how the transcription factor HNF4A—which controls...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Pittsburgh $100,228 on December 8, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of hepatocyte senescence in metabolic dysfunction-associated steatotic liver disease (MASLD). The research develops and employs a novel in vivo mouse model enabling selective induction of senescence in hepatocytes to examine the effects of...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Pittsburgh $550,070 on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct research elucidating ATP8B1 deficiency using patient-derived induced pluripotent stem cell (iPSC) models. The project addresses progressive familial intrahepatic cholestasis (PFIC) caused by ATP8B1 mutations, a rare inherited liver disease that impairs bile...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Pittsburgh $148,614 on March 9, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct mechanistic studies of amino acid deprivation-induced hepatic fibrosis. The research investigates how asparagine depletion during pegylated asparaginase (PEG-ASNASE) therapy causes hepatic fibrosis, a serious form of liver injury. PEG-ASNASE is used to treat...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Texas Health Science Center at Houston $154,332 on March 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of kynurenine-aryl hydrocarbon receptor signaling in cholestatic liver injury. The research examines how the kynurenine pathway and aryl hydrocarbon receptor activation regulate reactive oxygen species accumulation,...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Trustees of The University of Pennsylvania $665,725 on February 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct molecular genetic analysis of senescence in liver disease. The project develops and employs two innovative mouse models to address gaps in understanding how senescent cells contribute to liver injury, fibrosis, and cancer. The first model,...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Pittsburgh $556,648 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of FAN1 protein in preventing chronic kidney disease progression following acute kidney injury. The research targets DNA damage response and mitochondrial dysfunction in kidney tubular epithelial cells. The project will test whether enhancing...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Pittsburgh $812,862 on June 12, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to identify novel biomarkers of early progressive kidney function decline in type 1 diabetes. The research will use urinary and plasma peptidomics—analysis of synthesized peptides and protein degradation fragments—to discover prognostic markers that predict diabetic...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Pennsylvania $789,828 on June 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop theoretical models validated through experiments explaining the progression of metabolic dysfunction-associated steatotic liver disease (MASLD). The project develops and validates tissue-mechanics models to predict how cholesterol crystals in the liver drive...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The University of Texas Southwestern Medical Center $484,720 on June 22, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate ferroptotic damage mechanisms in acute pancreatitis and develop therapeutic interventions. The award funds basic and translational research into how the autophagy receptor SQSTM1 sensitizes pancreatic acinar cells to ferroptosis—a...